Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor‐Tyrosine Kinase Inhibitor Therapies

INTRODUCTION: Lenvatinib (Len) plus everolimus (Eve) is an approved therapy for metastatic renal cell carcinoma (mRCC) after first‐line vascular endothelial growth factor receptor‐tyrosine kinase inhibitors (VEGFR‐TKIs), but limited data exist on the efficacy of Len ± Eve after progression on immune...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Wiele, Andrew J., Bathala, Tharakeswara K., Hahn, Andrew W., Xiao, Lianchun, Duran, Munevver, Ross, Jeremy A., Jonasch, Eric, Shah, Amishi Y., Campbell, Matthew T., Msaouel, Pavlos, Tannir, Nizar M.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2021
Assuntos:
Genitourinary Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8176993/
https://ncbi.nlm.nih.gov/pubmed/33792094
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13770
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados